Portal Vein Embolization: Rationale, Technique, and Current Application
Executive Summary
Portal vein embolization (PVE) is a critical preoperative intervention designed to expand the population of patients eligible for curative hepatic resection. By redirecting portal blood flow to the non-tumor-bearing segments of the liver, PVE induces compensatory hyperplasia in the future liver remnant (FLR). This process mitigates the risks of postoperative liver insufficiency and hepatic dysfunction, which are independent predictors of surgical morbidity. Clinical data indicates that PVE is highly effective across various patient profiles, including those with normal liver function, cirrhosis, or those undergoing complex two-stage resections. With procedure-related mortality rates near 0% and a robust safety profile, PVE has become a standard of care in preparing patients for major hepatectomy.
Mechanisms of Liver Regeneration
The fundamental principle underlying PVE is the atrophy-hypertrophy complex, a controlled regenerative response to regional injury or vascular occlusion.
Hyperplasia over Hypertrophy: While the term "hypertrophy" is commonly used, regeneration is primarily driven by hyperplasia—an increase in cell number through mitosis rather than a mere increase in cell size.
Regenerative Capacity: The adult liver is typically quiescent, with fewer than 0.01% of cells undergoing mitosis. However, injury involving more than 10% of liver volume triggers a generalized response where up to 95% of cells may undergo mitosis. Following a two-thirds hepatectomy, the liver can regenerate its lost volume within approximately two weeks.
Biological Drivers: Regeneration is mediated by growth factors such as Hepatocyte Growth Factor (HGF), Transforming Growth Factor-α, and Tumor Necrosis Factor (TNF)-α. These factors work synergistically with insulin, which explains why patients with diabetes or insulin resistance may experience delayed regeneration.
PVE vs. Resection: Regeneration after PVE occurs more slowly than after surgical resection. This is attributed to PVE inducing apoptosis (programmed cell death) rather than the frank necrosis associated with surgery.
Clinical Assessment and Patient Selection
Determining the necessity for PVE requires a precise evaluation of both liver volume and functional reserve.
Standardized Future Liver Remnant (sFLR)
The absolute size of the FLR is insufficient for prediction because liver mass requirements vary by patient size. Clinicians use the Standardized FLR (sFLR), expressed as a ratio of FLR to Total Estimated Liver Volume (TELV). TELV is calculated using the Vauthey formula, which relies on Body Surface Area (BSA):
TELV = -794.41 + 1267.28 (BSA)
Indications for PVE
Patient selection is dictated by the underlying health of the liver and the complexity of the planned surgery:
Functional Reserve Testing
The Indocyanine Green (ICG) clearance test is utilized to quantify liver function. The ICG-R15 value (the percentage of dye remaining 15 minutes after injection) is the standard metric. Higher R15 values indicate decreased hepatic reserve, necessitating a larger FLR to ensure surgical safety.
Technical Considerations and Strategies
PVE aims for complete portal occlusion of diseased segments while sparing the FLR.
Embolic Agents: Various agents are used, including n-butyl cyanoacrylate (NBCA), ethiodized oil, fibrin glue, ethanol, and microparticles like trisacryl gelatin microspheres. Microspheres are often followed by the placement of coils to prevent recanalization.
Surgical vs. Percutaneous Approaches:
Transileocolic: A surgical approach requiring general anesthesia and a right lower quadrant incision. It avoids direct liver puncture but is more invasive.
Ipsilateral (Percutaneous): Access is through the tumor-bearing liver (the part to be resected). This is often preferred as it spares the FLR from potential injury, though it requires navigating acute angles using reverse curve catheters.
Contralateral (Percutaneous): Access is through the FLR. This allows for easier catheter manipulation and simultaneous interventions (like biliary drainage) but carries a risk of injuring the healthy liver remnant.
Contraindications
Absolute: Extensive ipsilateral tumor thrombus (portal flow is already diverted) and clinically evident portal hypertension.
Relative: Uncorrectable coagulopathy, renal insufficiency, and mild portal hypertension (due to risk of variceal bleeding).
Outcomes and Safety Profile
PVE is well-tolerated, often performed on an outpatient basis, and does not typically cause the "post-embolization syndrome" (fever, pain, nausea) seen in arterial embolization.
Hypertrophy Rates:
Normal Liver: 12 to 21 cm³/day (reaches sufficiency in 2–4 weeks).
Cirrhotic Liver: ~9 cm³/day (requires 4 or more weeks).
Morbidity and Mortality: Meta-analyses show a low overall morbidity of approximately 2.2% and procedure-related mortality of 0%.
Complications: Minor complications (e.g., subcapsular hematoma, transient liver failure) occur in up to 25% of cases. Major complications (e.g., complete portal vein thrombosis, nontarget embolization) occur in fewer than 5% of cases.
Advanced Clinical Applications
Sequential TACE and PVE
For patients with Hepatocellular Carcinoma (HCC) and cirrhosis, combining Transcatheter Arterial Chemoembolization (TACE) with PVE offers several benefits:
Counteracting the Buffer Response: PVE can increase hepatic arterial flow, potentially accelerating tumor growth; TACE provides local control to prevent this.
Enhanced Hypertrophy: Studies show a higher mean increase in sFLR for TACE+PVE (12.5%) compared to PVE alone (8.4%).
Improved Survival: Sequential therapy has been linked to higher 5-year disease-free survival rates (37% vs. 19%).
Two-Stage Hepatectomy
This approach provides a curative option for patients with bilobar colorectal metastases:
Stage 1: Resection or ablation of tumor within the FLR.
Interim: PVE to increase the mass of the now tumor-free FLR.
Stage 2: Major hepatectomy to remove the remaining diseased segments. Survival rates for patients completing both stages reach up to 64% at five years.
Future Directions: Stem Cell Integration
Research into the portal infusion of CD133+ bone marrow-derived stem cells in conjunction with PVE has shown promise. In one study, the stem cell group achieved significantly higher FLR growth (138.66 cm³) compared to PVE only (62.95 cm³) at 14 days post-treatment, suggesting a potential for even more rapid preoperative preparation.
